Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Patent metadata

Field	Value
Publication number	US-9920111-B2
Application number	US-201514692483-A
Country	US
Kind code	B2
Filing date	Apr 21, 2015
Priority date	Mar 17, 2009
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

First claim

What is claimed is:

1. A non-naturally occurring anti-HIV-1 PG9 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 45, 126 and 127 and (b) a heavy chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 7, 123 and 124.

2. A non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 41, 95 and 97 and (b) a heavy chain variable region comprising complementarity determining regions having the amino acid sequences of SEQ ID NOS: 6, 88 and 89.

3. A non-naturally occurring anti-HIV-1 PG9 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising amino acid sequence SEQ ID NO: 40 and (b) a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 39.

4. A non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising (a) a light chain variable region comprising amino acid sequence SEQ ID NO: 32 and (b) a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 31.

5. A non-naturally occurring anti-HIV-1 PG9 monoclonal antibody or antigen binding portion thereof comprising a heavy chain sequence of SEQ ID NO.: 28 and a light chain sequence of SEQ ID NO.: 30.

6. A non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising a heavy chain sequence of SEQ ID NO.: 12 and a light chain sequence of SEQ ID NO.: 14.

7. A pharmaceutical composition comprising the antibody of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

8. The antibody of any one of claims 1 - 6 , wherein the antigen is gp120.

Assignees

• Theraclone Sciences Inc
• Int Aids Vaccine Initiative
• Scripps Research Inst

Inventors

• Chan-Hui Po-Ying
• Frey Steven
• Olsen Ole
• Mitcham Jennifer
• Moyle Matthew
• Phogat Sanjay K
• Burton Dennis R
• Walker Laura Marjorie
• Poignard Pascal Raymond Georges
• Koff Wayne
• Simek-Lemos Melissa Danielle De Jean De St Marcel
• Kaminsky Stephen

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title